Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Accured Expenses (2016 - 2025)

Voyager Therapeutics' Change in Accured Expenses history spans 11 years, with the latest figure at -$3.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 216.71% year-over-year to -$3.2 million; the TTM value through Dec 2025 reached -$2.5 million, up 5.73%, while the annual FY2025 figure was -$2.5 million, 5.73% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$3.2 million at Voyager Therapeutics, down from $2.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.8 million in Q4 2023 and bottomed at -$9.3 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $422500.0 (2021), against an average of -$131400.0.
  • The largest annual shift saw Change in Accured Expenses surged 1065.84% in 2022 before it tumbled 7527.05% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$423000.0 in 2021, then crashed by 1007.33% to -$4.7 million in 2022, then surged by 223.21% to $5.8 million in 2023, then tumbled by 52.71% to $2.7 million in 2024, then crashed by 216.71% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Change in Accured Expenses are -$3.2 million (Q4 2025), $2.8 million (Q3 2025), and $3.0 million (Q2 2025).